We would like to welcome you to an in-person event on 30th September at Babraham Institute, Cambridge.
Join us to connect with experts in the multiomics space and find out how multiomics approaches are incorporated to advance precision medicine. During the 4 sessions, we will have a variety of speakers focusing on different angles of the multiomics spectrum, including epigenetics and proteomics. Learn how combining multiomics technologies has helped us gain deeper insights in health and disease and will continue to drive future healthcare development.
Date: 30th September 2022
Time: 10:00 - 14:00 GMT
Location: Babraham Insitute, Cambridge
Jens Fullgrabe
Associate Director of Assay Development
Cambridge Epigenetix
“DNA is more than just ACGT, expand your sequencing from 4 to 6 letters”
Paolo Piazza
Head of Innovation
University of Oxford
"First UK Olink service provider lab - our experience so far"
Dr Anne-Cecile Dingwall
Field Applications Scientist
Illumina
"Multiomics - Multidimensional analysis for every sample"
Dr Sarantis Chlamydas
Scientific Director
Olink Proteomics
"Precision proteomics broadens MultiOmics repertoire and enables biomarker discovery"
Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to develop our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways.
Olink is well-established in Europe (HQ Uppsala, Sweden) and the USA (HQ Boston, MA), with a rapidly developing presence across Asia. We also work with a growing number of core labs around the world offering analysis and support to an expanding global customer base.